In participants with highly active disease, the unadjusted annualized relapse rate (ARR) at Week 96 was 0.145 for BRIUMVI versus 0.496 for teriflunomide, representing a 70.8% relative reduction ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will present data ...
Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug ...
9d
A college student thought she had a UTI. Then came fevers, fatigue and pain: "Something's not right"
Emma Operacz was diagnosed with a rare cancer at 21. An unusual treatment and bone marrow donation from her sister saved her ...
If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chr ...
If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled ...
First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics License Application (sBLA) submission to U.S.
Lantidra therapy infuses healthy islet cells into patients' livers, with some achieving insulin independence. University ...
A father who has struggled to speak, sing or shout since he was a small boy has received a new treatment which means he can now read a bedtime story to his son. David Metherell, a 45-year-old critical ...
Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response ...
Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can ...
Lunsumio VELO, a subcutaneous CD20xCD3 bispecific antibody, is approved for relapsed or refractory follicular lymphoma after two systemic therapies. The GO29781 study reported a 75% objective response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results